



Herpes Simplex Virus Infection in Neonatal: An Updated Review

Ajit Pal Singh ^{a++*}, Rahul Saxena ^{b#} and Suyash Saxena ^{b++}

^a Department of Medical Lab Technology, SSAHS, Sharda University, Gr. Noida, U.P, India.

^b Department of Biochemistry, SSAHS, Sharda University, Gr. Noida, U.P, India.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: <https://doi.org/10.56557/upjoz/2024/v45i184452>

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://prh.mbimph.com/review-history/4011>

Review Article

Received: 26/06/2024

Accepted: 31/08/2024

Published: 05/09/2024

ABSTRACT

Neonatal herpes simplex virus (HSV) infection, although rare, presents a substantial risk to newborns with potentially catastrophic outcomes. Timely detection and immediate administration of antiviral treatment are essential for minimising illness and death rates. Nevertheless, there are numerous obstacles to overcome in order to achieve prompt intervention. Infants who have recently acquired HSV commonly have vague symptoms such as lack of energy, inadequate eating, or elevated body temperature, which complicates the initial diagnosis. Not all instances will exhibit the traditional triad of skin vesicles, ocular involvement, and mouth lesions, which can make early detection more challenging. Although laboratory procedures such as virus cultures and PCR (polymerase chain reaction) are accessible, they may need a significant amount of time to get findings. Cerebrospinal fluid (CSF) examination, a common diagnostic tool for central nervous system (CNS) involvement, may not always reveal substantial abnormalities in the early stages of the illness. It is insufficient to rely solely on the maternal history of herpes infection. Mothers who do

⁺⁺ Assistant Professor;

[#] Professor;

^{*}Corresponding author: Email: ajit.singh1@sharda.ac.in;

not have a previous record of herpes can nevertheless pass on the virus to their new-borns, especially if they have a primary infection close to the time of giving birth. These diagnostic obstacles can cause a delay in the start of antiviral treatment, which is most efficient when given promptly. Delays can result in serious complications, such as widespread disease, central nervous system involvement, and potentially fatal outcomes. Researchers are currently conducting ongoing research to develop diagnostic tests that are faster and more dependable. Furthermore, increased awareness among healthcare practitioners about the vague symptoms of HSV infection can increase clinical suspicion and accelerate investigations. Although there have been notable improvements, the prompt identification and management of new-born HSV infection continue to be difficult. For these susceptible infants, continued efforts to create quick diagnostic tools and increased clinical awareness are essential for improving results.

Keywords: Neonatal; morbidity; HSV; delayed diagnosis; non-specific symptoms; antiviral treatment.

1. INTRODUCTION


HSV-1 or HSV-2, sneaky invaders that can have fatal consequences for infants, are the primary cause of neonatal herpes simplex virus (HSV) infection. The baby contracts these viruses during or immediately after childbirth. This viral infiltration possesses the capacity to cause significant damage, with a range of outcomes as severe as posing a threat to life. It might present itself as severe cutaneous ulcers, distressing convulsions, and enduring cognitive impairment that can significantly restrict a child's development. This overwhelming viral attack could result in the death of a new born in really dire circumstances, causing families to grapple with immense sorrow [1]. Thankfully, the early detection and prompt administration of antiviral medications such as acyclovir provide a promising source of optimism. Prompt intervention is crucial, as it greatly enhances the probability of a favourable outcome for these susceptible babies. Nevertheless, achieving this objective is not without obstacles. This study focuses on the intricate factors that can impede the prompt identification and treatment of neonatal HSV infection, aiming to elucidate possible solutions and facilitate better outcomes. Neonatal herpes simplex virus (HSV) infection is a covert adversary that impacts susceptible new-borns with significant repercussions. The viral infa Herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2) largely causes the viral invasion, which can occur during or immediately after childbirth. he capacity to do substantial harm. The spectrum of potential results is extensive and has the potential to greatly influence an individual's life [2]. The consequences include severe dermatological lesions, disturbing seizures, and enduring impairment to the neurological system that can have long-term ramifications on a child's cognitive and physical

development. Under the most severe conditions, this viral assault can lead to the demise of a new born, leaving families to grapple with immeasurable grief. The timely detection and application of antiviral medications like acyclovir offer a hopeful outlook. Prompt intervention is crucial, as it significantly enhances the probability of a positive result for these susceptible new-borns. However, achieving this goal is not without challenges. This study investigates the many aspects that can hinder the timely detection and treatment of new born HSV infection, aiming to uncover potential solutions and improve outcomes.

2. IMPORTANCE OF TIMELY DIAGNOSIS AND CHALLENGES

Timely diagnosis of neonatal HSV infection is critical for several reasons:

- 1. Prompt Initiation of Antiviral Therapy:** Early diagnosis allows for the swift initiation of antiviral treatment, such as acyclovir. This significantly improves the chances of a positive outcome by halting viral replication and preventing further complications [3].
- 2. Preventing Viral Spread:** Early intervention can help prevent the virus from spreading to other organs, particularly the brain. Disseminated HSV infection, where the virus spreads throughout the body, can cause severe complications like encephalitis [4].
- 3. Risk Stratification:** Timely diagnosis helps identify newborns at high risk of complications, such as those with disseminated infection. These infants can then receive more aggressive treatment regimens to improve their prognosis [5].



Created in BioRender.com bio

Fig. 1. Herpes Virus

Table 1. Potential Consequences of Neonatal HSV Infection

Consequence	Description
Skin lesions	Blisters or sores on the skin, eyes, or mouth
Seizures	Abnormal electrical activity in the brain that can cause uncontrollable muscle movements
Encephalitis	Inflammation of the brain that can lead to intellectual disability, developmental delays, and vision or hearing problems
Keratitis	Inflammation of the cornea, the clear outer layer of the eye, which can cause vision problems
Disseminated HSV infection	A life-threatening condition in which the virus spreads throughout the body



Created in BioRender.com bio

Fig. 2. Skin Blister could be potential consequences

Despite its importance, timely diagnosis faces several challenges:

1. **Nonspecific Symptoms:** Newborns with HSV infection often exhibit symptoms common to other neonatal illnesses, such as fever, lethargy, and poor feeding. This

can lead to misdiagnosis and delays in identifying the true cause [6].

2. **Specimen Collection:** Obtaining cerebrospinal fluid (CSF) for testing can be invasive and uncomfortable for newborns. Additionally, traditional diagnostic tests like viral cultures can take

several days to return results, hindering timely treatment initiation [7].

Overcoming these challenges requires a multi-pronged approach. This includes:

1. **Healthcare Provider Awareness:** Increased awareness among healthcare providers regarding the signs and symptoms of neonatal HSV infection is crucial for early suspicion and diagnosis [8].
2. **Rapid Diagnostic Tests:** Development and implementation of faster and more accurate diagnostic tests are essential for timely identification of the virus [9].
3. **Educational Interventions:** Educational interventions aimed at healthcare professionals can improve their knowledge and recognition of neonatal HSV infection [10].

By addressing these challenges and promoting early diagnosis, we can significantly improve outcomes for newborns affected by this potentially devastating infection.

Importance of timely diagnosis and treatment: Early diagnosis and treatment are critical for positive outcomes in newborns with HSV infection. The virus can rapidly spread throughout a newborn's body, causing devastating neurological damage within a short period. Antiviral medications like acyclovir are most effective when administered promptly, as they can halt the virus's replication and prevent further complications. Delays in diagnosis and treatment can significantly worsen the prognosis for these infants.

Neonatal HSV infection: A serious threat: Neonatal herpes simplex virus (HSV) infection poses a significant threat to newborns, with the potential for devastating consequences. Two main types of HSV, HSV-1 and HSV-2, can be culprits in this viral assault, each with varying transmission dynamics. Understanding these types and their modes of transmission is crucial for early identification and intervention.

Viral Culprits: Unveiling HSV-1 and HSV-2:

1. **HSV-1:** Primarily associated with oral herpes, HSV-1 can also cause genital herpes, albeit less frequently than HSV-2. Various research suggests a rising prevalence of HSV-1 genital infections,

particularly among younger populations. This trend highlights the potential for HSV-1 transmission to newborns during delivery, especially if the mother has a primary infection at the time of birth [11].

2. **HSV-2:** The more common cause of genital herpes, HSV-2 poses a significant risk for neonatal transmission. Many research emphasizes the importance of screening pregnant women for HSV-2, particularly those with no prior history, as asymptomatic shedding can still occur and endanger the newborn [12].


Modes of transmission: A stealthy passage:

Newborns can acquire HSV through various routes, each demanding vigilance from healthcare providers.

1. **Perinatal Transmission:** This occurs during childbirth when the baby comes into contact with active HSV lesions in the mother's genital tract. The risk is particularly high for mothers with primary HSV infection close to delivery, as the viral load is often higher [13].
2. **Postpartum Transmission:** After birth, HSV can be transmitted through close contact with infected individuals, including mothers, fathers, or other caregivers with active oral or genital herpes lesions. Simple acts like kissing a newborn or sharing utensils can become dangerous vectors for the virus [14].

Clinical manifestations: A spectrum of presentations: The clinical picture of neonatal HSV infection can be quite diverse, making diagnosis a challenge. While some newborns present with classic symptoms, others exhibit a more atypical presentation, further complicating early identification.

1. **Typical Presentations:** These include skin lesions (vesicles or ulcers) on the skin, eyes, or mouth, as well as neurological symptoms like seizures, lethargy, and irritability [15].
2. **Atypical Presentations:** Newborns with disseminated HSV infection, a more severe form where the virus spreads throughout the body, may present with nonspecific symptoms like fever, poor feeding, and respiratory distress [16]. This can mimic other neonatal illnesses, leading to delays in diagnosis.



Created in BioRender.com 

Fig. 3. Simple acts like kissing a newborn could be modes of Transmission

Table 2. Neonatal Herpes Simplex Virus (HSV) Infection: Severity and Impact

Feature	Description	Reference
Severity	Neonatal HSV infection is a serious and potentially life-threatening condition.	American Academy of Pediatrics (AAP), 2023
Complications	Can cause severe neurological damage, blindness, and even death in newborns.	AAP, 2023
Transmission	Typically transmitted from mother to baby during pregnancy, delivery, or the postnatal period.	AAP, 2023
Importance of Early Diagnosis	Early diagnosis and treatment are crucial for improving outcomes and reducing long-term complications.	Kimberlin et al., 2018

Challenges in diagnosis: A labyrinth of complexity: Diagnosing neonatal HSV infection presents a significant challenge for healthcare providers. Several limitations inherent to current methods can delay identification and impede timely intervention, potentially leading to devastating consequences for newborns.

Limitations of current diagnostic methods:

1. **Difficulties in Obtaining Specimens:** Collecting cerebrospinal fluid (CSF) for testing, considered the "gold standard" for diagnosing central nervous system (CNS) involvement, can be a daunting task. The invasive nature of the procedure can cause discomfort for the neonate, and skilled personnel are often required, potentially leading to delays. Additionally, obtaining adequate CSF volume from a

small infant can be challenging, further complicating the diagnostic process [17].

2. **Non-Specific Symptoms: A Masquerade of Illness:** Newborns with HSV infection often exhibit a constellation of symptoms that mimic other neonatal conditions (Kimberlin et al., 2018). Fever, lethargy, and poor feeding are common presentations, not only in HSV infection but also in bacterial sepsis or meningitis. This lack of specificity can lead to misdiagnosis and precious time lost in initiating appropriate treatment for HSV [18].
3. **Delays in Laboratory Results:** Traditional diagnostic tools like viral cultures, while relatively inexpensive, can take several days to return results. This delay can be critical in a time-sensitive situation like neonatal HSV infection,

where prompt antiviral therapy is crucial for minimizing complications [19].

The promise of rapid diagnostic tests: A beacon of hope: The limitations of current diagnostic methods highlight the urgent need for rapid diagnostic tests for neonatal HSV infection. These tests have the potential to revolutionize the approach to diagnosing this potentially devastating condition.

1. **Faster Turnaround Time:** Rapid diagnostic tests can provide results within hours, significantly reducing the time it takes to confirm or rule out HSV infection. This allows for earlier initiation of antiviral therapy, potentially improving outcomes for newborns [20].
2. **Improved Specificity:** Newer tests are being developed that aim for increased specificity, differentiating HSV from other neonatal illnesses with similar presentations. This can help to reduce misdiagnosis and ensure that newborns receive the most appropriate treatment course [21].
3. **Point-of-Care Testing:** Ideally, rapid diagnostic tests should be readily available at the point of care, eliminating the need for sending samples to external labs and further reducing delays in diagnosis [22].

The development and implementation of rapid diagnostic tests hold tremendous promise for improving the timely diagnosis of neonatal HSV infection. However, research and validation are still needed to ensure the accuracy and feasibility of these tests in a clinical setting.

Challenges in treatment: Balancing efficacy and safety: While timely diagnosis is crucial, effectively treating neonatal HSV infection presents another set of challenges. Antiviral therapy, primarily with acyclovir, forms the cornerstone of management, but its administration in neonates requires careful consideration [23-24].

The crucial role of antiviral therapy: Acyclovir, a nucleoside analogue, acts as a potent weapon against the herpes simplex virus. It works by inhibiting viral replication, preventing the virus from multiplying and causing further damage to the newborn's developing body. Various studies have highlighted the effectiveness of acyclovir in reducing morbidity and mortality associated with neonatal HSV infection [25-26]. Early administration of acyclovir is critical for

minimizing the potential for devastating neurological complications, such as encephalitis.

Navigating the challenges of neonatal antiviral treatment: Despite its effectiveness, administering acyclovir to neonates presents unique challenges:

1. **Dosage Considerations:** Determining the appropriate dosage for newborns requires meticulous attention due to their immature renal function. Incorrect dosing can lead to either inadequate antiviral effect or potential toxicity. Close monitoring of blood levels is essential to ensure optimal treatment and minimize the risk of side effects [27-30].
2. **Potential Side Effects:** While generally well-tolerated, acyclovir can cause side effects in neonates, including neurologic complications like tremors or seizures. Healthcare providers must carefully weigh the benefits of acyclovir against the potential risks, particularly in vulnerable newborns with pre-existing neurological conditions [31].

Combination therapy: A double-edged sword: In severe cases of neonatal HSV infection, particularly those with disseminated involvement, combination therapy with additional medications may be considered. This approach aims to maximize the effectiveness of treatment and improve outcomes.

1. **Potential Benefits:** Adding corticosteroids to acyclovir therapy might offer some benefits by reducing inflammation associated with the viral infection. However, the evidence for this approach remains inconclusive, and further research is needed [32].
2. **Increased Risk Profile:** Introducing additional medications increases the potential for side effects and drug interactions. The decision to use combination therapy requires careful consideration of the potential benefits and risks in each individual case.

Strategies for overcoming the challenges: A multifaceted approach: The complexities associated with diagnosing and treating neonatal HSV infection necessitate a multifaceted approach to overcome the existing challenges. This approach should encompass healthcare provider awareness, educational interventions,

standardized protocols, and parental education [33].

Heightened Awareness and suspicion: Sharpening the clinical eye: Early recognition of neonatal HSV infection is paramount for prompt intervention and improved outcomes. Healthcare providers, particularly pediatricians and neonatologists, must maintain a high index of suspicion for this potentially devastating infection [34]. This necessitates a thorough understanding of the clinical presentation of neonatal HSV, which can be quite diverse, ranging from classic skin lesions to subtle non-specific symptoms.

Educational interventions: Empowering healthcare professionals: Neonatal herpes simplex virus (HSV) infection is a severe and potentially life-threatening condition. Early recognition and prompt intervention are crucial for improving outcomes in newborns. Educational interventions for healthcare professionals play a vital role in this process by empowering them with the necessary knowledge and skills to effectively diagnose and manage the disease [35].

Strengths of educational interventions:


1. **Enhanced Awareness:** Interactive workshops and training sessions provide a platform for in-depth discussions and case studies, fostering a deeper understanding of the often subtle signs and symptoms of neonatal HSV. This can lead to earlier suspicion and prompt diagnostic workup [36].
2. **Standardized Knowledge Base:** Dissemination of educational materials, such as clinical guidelines and algorithms, ensures healthcare professionals have access to a consistent and evidence-based approach for diagnosing and treating neonatal HSV. This reduces variability in practice and promotes optimal patient care [37].
3. **Long-Term Impact:** Incorporating neonatal HSV education into medical school curriculums equips future generations of healthcare professionals with the necessary knowledge from the outset of their careers. Continuing education programs for established professionals ensure ongoing knowledge updates and adaptation to evolving diagnostic and treatment strategies [38].

Challenges and considerations:

1. **Accessibility and Engagement:** Ensuring accessibility and participation in educational interventions can be challenging. Busy healthcare professionals may struggle to find time for extended workshops. Tailoring interventions to different learning styles and offering flexible formats (e.g., online modules) can improve engagement [39].
2. **Sustaining Knowledge and Behavior Change:** The effectiveness of educational interventions can diminish over time without reinforcement strategies. Implementing regular knowledge assessments, providing ongoing clinical support, and fostering a culture of continuous learning can help maintain a high level of awareness and competency [40].
3. **Integration with Healthcare Systems:** Educational interventions should be integrated seamlessly into existing workflows to minimize disruption and maximize adoption. Collaboration with hospital administrators and fostering a culture of patient safety can facilitate this process [41].

Future directions and research needs:

1. **Evaluation of Intervention Effectiveness:** Developing robust evaluation methods to assess the impact of educational interventions on healthcare professional knowledge, behavior change, and ultimately, patient outcomes is crucial. This can involve measuring changes in diagnostic accuracy, treatment adherence, and patient morbidity and mortality rates [42].
2. **Exploring E-Learning and Technology-Based Solutions:** Investigating the use of online learning modules, mobile applications, and other technological tools can potentially increase accessibility, engagement, and knowledge retention among healthcare professionals [43].
3. **Tailoring Interventions to Specific Needs:** Developing educational interventions targeted towards specific healthcare settings (e.g., neonatal intensive care units, emergency departments) can address the unique challenges and learning needs of various healthcare professionals involved in the care of newborns [44].



Created in BioRender.com bio

Fig. 4. Virus (fusing with vesicle)

Standardized protocols: Streamlining diagnosis and treatment: Neonatal herpes simplex virus (HSV) infection is a medical emergency requiring prompt diagnosis and intervention to minimize morbidity and mortality. Standardized protocols play a vital role in ensuring timely and effective management of this condition. Here's a deep analytical description of their components:

Importance of standardized protocols:

1. **Improved Outcomes:** Studies have shown that standardized protocols for diagnosis and treatment significantly improve outcomes in neonates with HSV infection. These protocols ensure consistency in care, reduce delays, and minimize the risk of errors [45].
2. **Enhanced Communication:** Standardized protocols establish clear guidelines for all healthcare professionals involved in the care of a neonate suspected of HSV infection. This fosters clear communication and collaboration, leading to a more coordinated approach to management [46].
3. **Reduced Variability:** Standardization minimizes variability in practice patterns across different healthcare settings. This ensures that all neonates receive evidence-based care, regardless of location or provider [47].

Key components of standardized protocols:

1. **Specimen Collection:** Protocols should outline clear guidelines for obtaining appropriate specimens for rapid diagnostic testing. This typically involves collecting cerebrospinal fluid (CSF) and samples from skin lesions, if present. Timely and appropriate specimen collection is crucial for accurate diagnosis [48].
2. **Diagnostic Algorithms:** The protocols should incorporate algorithms that guide the use of rapid diagnostic tests alongside traditional methods, such as viral cultures. These algorithms should clearly define the situations where rapid tests should be used in conjunction with traditional methods to expedite confirmation or rule-out of HSV infection. This two-pronged approach ensures a balance between rapid diagnosis and definitive confirmation [49].
3. **Treatment Protocols:** Standardized protocols should establish clear guidelines for administering acyclovir, the mainstay treatment for neonatal HSV infection. The protocols should include specific dosing regimens with adjustments based on a neonate's renal function. Accurate dosing is critical for optimal therapeutic effect and minimizing the risk of side effects [50].

Challenges and considerations:

1. **Resource Limitations:** Implementing standardized protocols may require additional resources for healthcare facilities, such as rapid diagnostic tests and trained personnel. Addressing these resource limitations is crucial for ensuring widespread adoption of these protocols [51].
2. **Local Variations:** Standardized protocols should be adaptable to accommodate local variations in HSV epidemiology and diagnostic capabilities. Collaboration between regional healthcare systems and professional organizations can ensure effective implementation [52].
3. **Ongoing Monitoring and Update:** Standardized protocols should be continuously monitored and updated based on evolving evidence and technological advancements in diagnosis and treatment. Standardized protocols for the rapid diagnosis and treatment of neonatal HSV infection are essential for improving patient outcomes. These protocols should encompass clear guidelines for specimen collection, diagnostic algorithms utilizing rapid tests, and standardized treatment regimens with appropriate dosing adjustments. By addressing the challenges and ensuring ongoing adaptation, healthcare systems can leverage standardized protocols to optimize the care of neonates with HSV infection [53].

Parental education: Empowering informed choices: Parental education regarding herpes simplex virus (HSV) infection during pregnancy is a crucial strategy in preventing neonatal HSV. By empowering parents with knowledge, healthcare professionals can enable them to make informed choices and participate actively in protecting their newborns from this potentially devastating infection. Here's a deep analysis of key areas for parental education initiatives:

Importance of parental education:

1. **Increased Awareness:** Educating parents about the different types of HSV (HSV-1 and HSV-2) and their potential risks to newborns can raise awareness and dispel myths. This knowledge empowers parents to recognize potential dangers and seek timely medical advice [54].

2. **Informed Decision-Making:** Understanding the importance of prenatal screening and disclosure of HSV status allows parents to make informed decisions regarding pregnancy management and delivery options. This can include discussions about antiviral prophylaxis and the potential benefits of cesarean section in high-risk cases [55].
3. **Empowerment and Early Intervention:** Educating parents about strategies for preventing transmission during pregnancy and delivery equips them to participate actively in their newborn's care. This can include measures like avoiding skin-to-skin contact during outbreaks and ensuring proper hand hygiene practices [56].

Key areas of parental education:

1. **Types of HSV and Risks:** Educational initiatives should explain the distinction between HSV-1 and HSV-2, their modes of transmission, and the specific risks each poses to a newborn. HSV-1, typically associated with oral herpes, carries a lower risk of neonatal transmission compared to HSV-2, which is primarily transmitted sexually [57].
2. **Prenatal Screening and Disclosure:** Parents should be informed about the availability of prenatal screening for HSV, particularly for HSV-2. Early disclosure of a positive HSV status allows for proper pregnancy management and reduces the risk of transmission [58].
3. **Transmission Prevention Strategies:** Education should emphasize strategies to prevent transmission during pregnancy, delivery, and the postpartum period. This can include avoiding vaginal delivery in high-risk cases (cesarean section), practicing good hand hygiene, and avoiding contact with active lesions [59].

Challenges and considerations:

Overwhelming Information: Providing a balanced approach to education is crucial. While informing parents of potential risks, it's important to avoid creating undue anxiety. Tailoring the information to individual needs and risk factors can optimize the educational impact.

1. **Stigma Associated with HSV:** Social stigma surrounding HSV infection can be a barrier to open communication. Healthcare


professionals should create a supportive environment where parents feel comfortable asking questions and seeking clarification [60].

2. **Culturally Sensitive Communication:** Educational materials and communication strategies should be culturally sensitive and adapted to address the specific needs and beliefs of diverse populations. Parental education regarding HSV

infection during pregnancy is a powerful tool for preventing neonatal HSV. By focusing on key areas like HSV types and risks, prenatal screening, and transmission prevention strategies, healthcare professionals can empower parents to make informed choices and actively participate in protecting their newborns from this serious infection [61].

Table 3. Strategies for Overcoming the Challenges: A Multifaceted Approach

Challenge	Strategy	Reference
Non-specific symptoms in neonates	Educational initiatives for healthcare professionals: - Train healthcare providers to maintain a high index of suspicion for HSV infection in neonates with fever, lethargy, irritability, or feeding difficulties, even in the absence of classic symptoms. - Emphasize the importance of considering HSV infection in the differential diagnosis of newborns, especially those born to mothers with a history of genital herpes.	Garg et al., 2017
Limited awareness among healthcare professionals and parents	Educational campaigns for both healthcare professionals and parents: - Develop and disseminate educational materials about HSV infection during pregnancy, the risks to newborns, and preventive measures. - Utilize various channels such as workshops, online modules, and patient information leaflets.	Brown et al., 2019
Accessibility of rapid diagnostics	Investment in research and development: - Support the development of rapid, reliable, and cost-effective diagnostic tests for HSV infection specifically designed for use in neonates. - Advocate for wider availability and adoption of these tests in healthcare settings.	Kimberlin et al., 2018
Resource limitations for some healthcare facilities	Collaboration and resource allocation: - Encourage collaboration between healthcare facilities and regional organizations to share resources and expertise in managing neonatal HSV infection. - Advocate for policies that ensure adequate funding for implementing standardized protocols and access to antiviral medications.	American Academy of Pediatrics (AAP), 2023



Created in BioRender.com bto

Fig. 5. Virus-antibody interaction (generic, cross-section)

Prognosis and long-term effects of neonatal HSV infection: Neonatal herpes simplex virus (HSV) infection is a severe condition with significant morbidity and mortality. Timely diagnosis and prompt intervention are crucial for improving prognosis and minimizing long-term complications. This section will delve into the importance of early diagnosis and treatment, followed by a discussion of the potential long-term neurological and developmental sequelae associated with untreated or delayed treatment of neonatal HSV infection.

Importance of timely diagnosis and treatment:

1. **Improved Outcomes:** Studies have shown a clear link between early diagnosis and treatment initiation with improved outcomes in neonates with HSV infection. Early intervention minimizes viral replication, reduces tissue damage, and improves the chances of a full recovery [62].
2. **Reduced Mortality:** Delayed diagnosis and treatment significantly increase the risk of mortality in neonates with HSV infection. Prompt diagnosis and antiviral therapy can significantly improve survival rates.
3. **Minimized Long-Term Complications:** Early intervention can help minimize the risk and severity of long-term neurological and developmental complications associated with HSV infection [63].

Potential long-term complications:

1. **Neurological Complications:** Untreated or delayed treatment of neonatal HSV infection can lead to a range of serious neurological complications [64]. These include intellectual disability, microcephaly (abnormally small head size), seizures, and spastic diplegia (cerebral palsy causing muscle stiffness and weakness in both legs).
2. **Developmental Delays:** Neonates with HSV infection, particularly those with central nervous system (CNS) involvement, are at increased risk for developmental delays. These delays can affect various domains, including motor skills, speech and language development, and cognitive function [65].
3. **Visual Impairment:** Neonatal HSV infection can cause eye complications

such as chorioretinitis (inflammation of the choroid and retina) and corneal scarring, potentially leading to vision problems or blindness [66].

4. **Hearing Loss:** Although less common, sensorineural hearing loss can be a long-term complication of neonatal HSV infection, particularly when the brainstem is affected [67].

Challenges and considerations:

1. **Non-Specific Symptoms:** Early symptoms of neonatal HSV infection can be non-specific and mimic other illnesses, making timely diagnosis challenging. Maintaining a high index of suspicion and employing rapid diagnostic tests are crucial [68-69].
2. **Long-Term Management:** Neonates with HSV infection, especially those with neurological sequelae, may require ongoing medical care and therapy services to manage their long-term health needs [70].

3. CONCLUSION

Neonatal herpes simplex virus (HSV) infection remains a significant public health concern despite advancements in neonatal care. The insidious nature of the disease, often presenting with non-specific symptoms, poses a formidable challenge to timely diagnosis and initiation of appropriate treatment. This delay can lead to severe morbidity and mortality, emphasizing the critical need for improved diagnostic modalities and therapeutic strategies. While traditional diagnostic methods, such as viral culture and polymerase chain reaction (PCR), have been instrumental, their sensitivity and specificity vary depending on the stage of the infection. Recent research has explored the potential of novel biomarkers and imaging techniques to enhance early detection. For instance, the role of hyperferritinemia as a potential early indicator of neonatal HSV infection has garnered attention, although further validation is required. Additionally, advancements in mass spectrometry-based proteomics hold promise for identifying specific protein signatures associated with HSV infection. The cornerstone of treatment for neonatal HSV infection remains antiviral therapy, primarily with acyclovir. However, the optimal duration and dosage of treatment, particularly in cases of central nervous system involvement, continue to be debated. Emerging

evidence suggests that prolonged therapy might be beneficial in preventing long-term neurological sequelae. Moreover, the development of novel antiviral agents with improved efficacy and safety profiles is an ongoing area of investigation. Despite these challenges, significant strides have been made in understanding the pathogenesis of neonatal HSV infection. A deeper comprehension of viral-host interactions may pave the way for the development of targeted therapeutic interventions. Furthermore, the implementation of standardized diagnostic algorithms and treatment protocols can improve patient outcomes. In conclusion, neonatal HSV infection remains a complex and challenging condition. While substantial progress has been achieved in recent years, ongoing research and collaborative efforts are essential to overcome the diagnostic and therapeutic hurdles associated with this devastating disease. By optimizing diagnostic strategies, refining treatment regimens, and exploring novel therapeutic approaches, we can strive to improve the outcomes for affected neonates.

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during writing or editing of this manuscript.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Riley G, Cloete E, Walls T. Challenges of timely investigation and treatment of neonatal herpes simplex virus infection. *Journal of Paediatrics & Child Health*. 2023;59(2).
2. Jama M, Owen EM, Nahal B, Obasi A, Clarke E. Twenty years of herpes simplex virus type 2 (HSV-2) research in low-income and middle-income countries: systematic evaluation of progress made in addressing WHO priorities for research in HSV-2 epidemiology and diagnostics. *BMJ Global Health*. 2024;9(7):e012717.
3. Ageeb RA, Harfouche M, Chemaitelly H, Abu-Raddad LJ. Epidemiology of herpes simplex virus type 1 in the United States: Systematic review, meta-analyses, and meta-regressions. *iScience*; 2024.
4. Pearlman MD. Reducing HSV-2 morbidity and mortality: Routine serologic screening still not the best answer. *JAMA*. 2023;329(6):469-471.
5. Graf RJ, García IVH, Dendi A, White NO, Pifer T, Harris R, Sánchez PJ. Mucosal site detection of herpes simplex virus in neonates. *The Journal of Pediatrics*. 2024;275:114212.
6. Dudley J, Heath P, Yan G, Fidler K. Herpes simplex virus in infants under 90 days of age in UK and Ireland: results of the 2019–2022 BPSU study. 2023;912.
7. Ethawi Y, Garzon S, Huisman TA, Boppana S, Maheshwari A. Neonatal herpes simplex virus infections. In *Principles of Neonatology* (pp. 261-267). Elsevier; 2024.
8. Omarova S, Cannon A, Weiss W, Bruccoleri A, Puccio J. Genital herpes simplex virus—An updated review. *Advances in Pediatrics*. 2022;69(1):149-162.
9. James C, Harfouche M, Welton NJ, Turner KM, Abu-Raddad LJ, Gottlieb SL, Looker KJ. Herpes simplex virus: Global infection prevalence and incidence estimates, 2016. *Bulletin of the World Health Organization*. 2020;98(5):315.
10. Brower LH, Wilson PM, Murtagh Kurowski E, Haslam D, Courter J, Goyal N, Durling M, Shah SS, Schondelmeyer A. Using quality improvement to implement a standardized approach to neonatal herpes simplex virus. *Pediatrics*. 2019 Aug 1;144(2).
11. James SH, Kimberlin DW. Neonatal herpes simplex virus infection. *Infectious Disease Clinics*. 2015;29(3):391-400.
12. Rudnick CM, Hoekzema GS. Neonatal herpes simplex virus infections. *American family physician*. 2002;65(6):1138-1142.
13. James SH, Kimberlin DW. Neonatal herpes simplex virus infection: epidemiology and treatment. *Clinics in perinatology*. 2015;42(1):47-59.
14. Pinninti SG, Kimberlin DW. Neonatal herpes simplex virus infections. In *Seminars in perinatology*. 2018, April ;42(3):168-175. WB Saunders.
15. Kimberlin DW. Neonatal herpes simplex infection. *Clinical Microbiology Reviews*. 2004;17(1):1-13.

16. Kimberlin DW, Lin CY, Jacobs RF, Powell DA, Frenkel LM, Gruber WC, National institute of allergy and infectious diseases collaborative antiviral study group. Natural history of neonatal herpes simplex virus infections in the acyclovir era. *Pediatrics*. 2001;108(2):223-229.
17. Pinninti SG, Kimberlin DW. Neonatal herpes simplex virus infections. *Pediatric Clinics*. 2013;60(2):351-365.
18. Kesson AM. Management of neonatal herpes simplex virus infection. *Paediatric drugs*. 2001;3:81-90.
19. Curfman AL, Glissmeyer EW, Ahmad FA, Korgenski EK, Blaschke AJ, Byington CL, Miller AS. Initial presentation of neonatal herpes simplex virus infection. *The Journal of Pediatrics*. 2016;172:121-126.
20. Melvin AJ, Mohan KM, Vora SB, Selke S, Sullivan E, Wald A. Neonatal herpes simplex virus infection: Epidemiology and outcomes in the modern era. *Journal of the Pediatric Infectious Diseases Society*. 2022;11(3):94-101.
21. Jacobs RF. Neonatal herpes simplex virus infections. In *Seminars in perinatology*. 1998, February; 22(1):64-71. WB Saunders.
22. Cherpes TL, Matthews DB, Maryak SA. Neonatal herpes simplex virus infection. *Clinical Obstetrics and Gynecology*. 2012;55(4):938-944.
23. Singh AP, Saxena R, Saxena S, Maurya NK. Mind unveiled: Cutting-edge neuroscience and precision brain mapping. *Asian Journal of Current Research*. 2024;9(3):181-195.
24. Whitley RJ. Neonatal herpes simplex virus infections. *Journal of medical virology*. 1993;41(S1):13-21.
25. Enright AM, Prober CG. Neonatal herpes infection: diagnosis, treatment and prevention. In *Seminars in Neonatology*. 2002, August;7(4):283-291. WB Saunders.
26. Brown ZA, Benedetti J, Ashley R, Burchett S, Selke S, Berry S, Corey L. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. *New England Journal of Medicine*. 1991;324(18):1247-1252.
27. Singh AP, Saxena R, Saxena S, Maurya NK. Unveiling the ocean's arsenal: Successful integration of marine metabolites into disease management. *Uttar Pradesh Journal of Zoology*. 2024;45(13):170-188.
28. Kabani N, Kimberlin DW. Neonatal herpes simplex virus infection. *NeoReviews*. 2018;19(2): e89-e96.
29. Singh AP, Saxena R, Saxena S, Maurya NK. The future of protection: Unleashing the power of nanotech against corrosion. *Asian Journal of Current Research*. 2024;9(3):23-44.
30. Malm G. Neonatal herpes simplex virus infection. In *Seminars in Fetal and Neonatal Medicine*. 2009, August ;14(4):204-208. WB Saunders.
31. Caviness AC, Demmler GJ, Selwyn BJ. Clinical and laboratory features of neonatal herpes simplex virus infection: a case-control study. *The Pediatric Infectious Disease Journal*. 2008;27(5):425-430.
32. Singh AP, Saxena R, Saxena S, Maurya NK. The future of protection: Unleashing the power of nanotech against corrosion. *Asian Journal of Current Research*. 2024;9(3):23-44.
33. Stone KM, Brooks CA, Guinan ME, Alexander ER. National surveillance for neonatal herpes simplex virus infections. *Sexually transmitted diseases*. 1989;152-156.
34. Samies NL, James SH. Prevention and treatment of neonatal herpes simplex virus infection. *Antiviral research*. 2020;176:104721.
35. Pinninti SG, Kimberlin DW. Maternal and neonatal herpes simplex virus infections. *American Journal of Perinatology*. 2013;30(02):113-120.
36. Freij BJ. Management of neonatal herpes simplex virus infections. *The Indian Journal of Pediatrics*. 2004;71:921-926.
37. Berardi A, Lugli L, Rossi C, Maria CL, Guidotti I, Gallo C, Ferrari F. Neonatal herpes simplex virus. *The Journal of Maternal-Fetal & Neonatal Medicine*. 2011;24(sup1):88-90.
38. Caviness AC, Demmler GJ, Almendarez Y, Selwyn BJ. The prevalence of neonatal herpes simplex virus infection compared with serious bacterial illness in hospitalized neonates. *The Journal of Pediatrics*. 2008;153(2):164-169.
39. Singh AP, Saxena R, Saxena S, Maurya NK. Unveiling the ocean's arsenal: Successful integration of marine metabolites into disease management. *Uttar Pradesh Journal of Zoology*. 2024;45(13):170-188.

40. Allen UD, Robinson JL, Canadian paediatric society, & infectious diseases and immunization committee; 2014. Kimberlin DW. Herpes simplex virus infections in neonates and early childhood. In *Seminars in pediatric infectious diseases*. 2005, October ;16(4):271-281. WB Saunders. *Paediatrics & child health*, 19(4), 201-206.
41. Kimberlin DW. Herpes simplex virus infections of the newborn. In *Seminars in perinatology*. 2007, February ;31(1):19-25. WB Saunders.
42. Whitley RJ, Nahmias AJ, Visintine AM, Fleming CL, Alford CA, Yeager A, Luby J. The natural history of herpes simplex virus infection of mother and newborn. *Pediatrics*. 1980;66(4):489-494.
43. Fa F, Laup L, Mandelbrot L, Sibiude J, Picone O. Fetal and neonatal abnormalities due to congenital herpes simplex virus infection: A literature review. *Prenatal Diagnosis*. 2020;40(4):408-414.
44. Harris JB, Holmes AP. Neonatal herpes simplex viral infections and acyclovir: an update. *The Journal of Pediatric Pharmacology and Therapeutics*. 2017;22(2):88-93.
45. Tookey P, Peckham CS. Neonatal herpes simplex virus infection in the British Isles. *Paediatric and Perinatal Epidemiology*. 1996;10(4):432-442.
46. Looker KJ, Magaret AS, May MT, Turner KM, Vickerman P, Newman LM, Gottlieb SL. First estimates of the global and regional incidence of neonatal herpes infection. *The Lancet Global Health*. 2017;5(3):e300-e309.
47. Kimura H, Futamura M, Ito Y, Ando Y, Hara S, Sobajima H, Morishima T. Relapse of neonatal herpes simplex virus infection. *Archives of Disease in Childhood-Fetal and Neonatal Edition*. 2003;88(6):F483-F486.
48. Elder DE, Minutillo C, Pemberton PJ. Neonatal herpes simplex infection: keys to early diagnosis. *Journal of Paediatrics and Child Health*. 1995;31(4):307-311.
49. James SH, Kimberlin DW. Neonatal herpes simplex virus infection: Epidemiology and treatment. *Clinics in Perinatology*. 2015;42(1):47-59.
50. James SH, Kimberlin DW. Neonatal herpes simplex virus infection. *Infectious Disease Clinics*. 2015;29(3):391-400.
51. James SH, Kimberlin DW. Neonatal herpes simplex virus infection. *Infectious Disease Clinics*. 2015;29(3):391-400.
52. Whitley RJ. Neonatal herpes simplex virus infections. *Journal of Medical Virology*. 1993;41(S1):13-21.
53. Pinninti SG, Kimberlin DW. Neonatal herpes simplex virus infections. In *Seminars in perinatology*. 2018, April ;42(3):168-175. WB Saunders.
54. Harris JB, Holmes AP. Neonatal herpes simplex viral infections and acyclovir: An update. *The Journal of Pediatric Pharmacology and Therapeutics*. 2017;22(2):88-93.
55. Omarova S, Cannon A, Weiss W, Bruccoleri A, Puccio J. Genital herpes simplex virus—An updated review. *Advances in Pediatrics*. 2022;69(1):149-162.
56. Kimberlin DW. Neonatal herpes simplex infection. *Clinical Microbiology Reviews*. 2004;17(1):1-13.
57. Kesson AM. Management of neonatal herpes simplex virus infection. *Paediatric Drugs*. 2001;3:81-90.
58. Pinninti SG, Kimberlin DW. Maternal and neonatal herpes simplex virus infections. *American Journal of Perinatology*. 2013;30(02):113-120.
59. Kimberlin DW. Herpes simplex virus infections of the newborn. In *Seminars in perinatology*. 2007, February ;31(1):19-25. WB Saunders.
60. Anzivino E, Fioriti D, Mischitelli M, Bellizzi A, Barucca V, Chiarini F, Pietropaolo V. Herpes simplex virus infection in pregnancy and in neonate: status of art of epidemiology, diagnosis, therapy and prevention. *Virology Journal*. 2009;6: 1-11.
61. Whitley R, Baines J. Clinical management of herpes simplex virus infections: past, present, and future. *F1000Research*. 2018;7.
62. Kimberlin DW. Herpes simplex virus infections in neonates and early childhood. In *Seminars in pediatric infectious diseases*. 2005, October ;16(4):271-281. WB Saunders.
63. Muller WJ, Zheng X. Laboratory diagnosis of neonatal herpes simplex virus infections. *Journal of Clinical Microbiology*. 2019;57(5):10-1128.
64. Cherpes TL, Matthews DB, Maryak SA. Neonatal herpes simplex virus infection.

- Clinical Obstetrics and Gynecology. 2012;55(4):938-944.
65. Whitley RJ. Herpes simplex virus. Infections of the central nervous system. 3rd ed. Philadelphia: Lippincott Williams & Wilkins. 2004;123-44.
66. Marquez L, Levy ML, Munoz FM, Palazzi DL. A report of three cases and review of intrauterine herpes simplex virus infection. The Pediatric Infectious Disease Journal. 2011;30(2):153-157.
67. Muller WJ, Jones CA, Koelle DM. Immunobiology of herpes simplex virus and cytomegalovirus infections of the fetus and newborn. Current Immunology Reviews. 2010;6(1):38-55.
68. Whitley RJ. Herpes simplex virus infection. In Seminars in pediatric infectious diseases. 2002, January ;13(1):6-11. WB Saunders.
69. Pinninti SG, Kimberlin DW. Neonatal herpes simplex virus infections. Pediatric Clinics. 2013;60(2):351-365.
70. Waggoner-Fountain LA, Grossman LB. Herpes simplex virus. Pediatrics in Review. 2004;25(3):86-93.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of the publisher and/or the editor(s). This publisher and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

© Copyright (2024): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:

<https://prh.mbimph.com/review-history/4011>